secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001140361-24-016666
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma names Aaron Ondrey CFO; expands leadership team for commercial transition
--------------------------------------------------------------------------------

- Aaron Ondrey appointed CFO, effective March 25, 2024; previously CFO of Mirati Therapeutics.
- Compensation: base salary $485k, target bonus 45%, equity grant ~$2.5M (half options, half RSUs) with 3-year vesting.
- Other appointments: Kinnari Patel as President/Head of R&D/COO; Jonathan Schwartz as Chief Medical & Gene Therapy Officer; Mark White as GM Commercial; Martin Wilson as GC/Chief Corporate Officer.
- Leadership changes position Rocket for planned commercial stage transition for gene therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124016666/0001140361-24-016666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124016666/ef20025500_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-016666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer